Macrolides: Not just antibiotics;Macrólidos, no sólo antibióticos

Archivos de Bronconeumologia

Volumn 44, Issue 5, 2008, Pages 229-232

  Girón, Rosa María ^a   Ancochea, Julio ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450; ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MACROLIDE; NITRIC OXIDE; PLACEBO; ROXITHROMYCIN;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CAMPYLOBACTER; CHLAMYDIA; CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; HAEMOPHILUS; HUMAN; IMMUNOMODULATION; LEGIONELLA; LUNG TRANSPLANTATION; MORAXELLA; MYCOPLASMA; PNEUMONIA; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION;

EID: 45549088143     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13119936     Document Type: Editorial

References (48)

1. Haely DP. Macrolide immunomodulation of chronic respiratory diseases. Currt Infect Dis Rep. 2007;9:7-13.
2. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung diseases. Pediatr Pulmonol. 2001;31:464-73.
3. Mensa J, Gracía-Vazquez E, Vila J. Macrólidos, cetólidos y estreptograminas. Enferm Infecc Microbiol Clin. 2003;21:200-8.
4. McArdle J, Talwalkar J. Macrolides in cystic fibrosis. En: Whitaker L, editor. Cystic fibrosis. Philadelphia: Saunders; 2007. p. 347-60.
5. Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001;45:1930-3.
6. Baumann U, Fischer J, Gudowius P, Lingner M, Herrmann S, Tümmler B, et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis and long-term therapy with azithromycin. Infection. 2001;29:7-11.
7. Nguyen D, Emond M, Mayer-Hamblett N, Saiman L, Marshall B, Burns J. Clinical response to azithromycin in cystic fibrosis corelates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol. 2007;42:533-41.
8. Imamura Y, Yanagihara K, Mizuta Y, Seki M, Ohno H, Higashiyama Y, et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-oxododecanoyl) homoserine lactone in NCL-H292 cells. Antimicrob Agents Chemother. 2004;48:3457-61.
9. Tamaoki J, Takeyama K, Tagaya E, Cono K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother. 1995;39:1688-90.
10. Pradal U, Delmarco A, Morganti M, Cipolli M, Mini E, Cazzola G. Long-term azithromycin in cystic fibrosis: another posible mechanism of action? J Chemother. 2005;17:393-400.
11. Wagner T, Burns J. Anti-inflammatory properties of macrolides. Pediatr Infect Dis J. 2007;26:75-6.
12. Cigana C, Asale B, Melotti P. Azithomycin selectively reduces tumor necrosis factor alpha level in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2007;51:975-81.
13. Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al. Azithomicin modulates neutrophil function andcirculating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277-89.
14. Tsai W, Rodríguez M, Young K, Deng JC, Thannickal VJ, Tateda K, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Care Med. 2004;170:1331-9.
15. Ferrara G, Losi M, Franco F, Corbetta L, Fabbri L, Richeldi L. Macrolides in the treatment of asthma and cystic fibrosis. Respir Med. 2005;99:1-10.
16. Johnston S. Macrolide antibiotics and asthma treatment. J Allergy Clin Immunol. 2006;117:1233-6.
17. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2005;(3):CD002997.
18. Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H. Anti-inflammtory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy. 1999;29: 950-6.
19. Kamada AK, Hill M, Ikle D, Brenner A, Szefler S. Efficacy and safety of low-dose troleandomycin therapy in children with severe steroid requiring asthma. J Allergy Clin Immunol. 1993;91: 873-82.
20. Nelson H, Camilos D, Corsello P, Levesque N, Buchmeier A, Bucher B. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require dayly corticosteroids. Am Rev Respir Dis. 1993;147:398-404.
21. Kraft M, Cassell G, Pak J, Martin R. Micoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest. 2002;121:1782-8.
22. Black P, Jenkins C, Scicchitano R, Blasi F, Allegar L, Mills G, et al. Trial of roxitromycin in subject with asthma and serologycal evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med. 2001;164: 536-41.
23. Kostadima E, Tsiodras S, Alexopoulos E, Kaditis A, Mavrou I, Georgatou N, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J. 2004;23:714-7.
24. Amayasu H, Yacida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, et al. Clarithromycin supress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol. 2000;84:594-8.
25. Schultz M. Macrolide activities beyond their antimicronial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother. 2004;54:21-8.
26. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-32.
27. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003;97:844-50.
28. Southern K, Barrer P, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2004;(2):CD002203.
29. Equi A, Balfour-Lynn I, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;28:978-84.
30. Wolter J, Seeney S, Bell S, Bowler S, Mases P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57:212-6.
31. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med. 2004;10:515-23.
32. Cipolli M, Cazzola G, Novelli A, Caseta M, Fallani S, Mazzei T. Azithromycin concentration in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest. 2001;21:353-60.
33. Saiman L, Mayer-Hamblett N, Campbell P, Marshall B, Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med. 2005;172:1008-12.
34. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006;61:895-902.
35. Tsang K, Ho P, Chan K, Ip M, Lam W, Ho C, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J. 1999;13:361-4.
36. Koh Y, Lee M, Sun Y, Sung K, Chae J. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled stydy. Eur Respir J. 1997;10:994-9.
37. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax. 2004;59:540-1.
38. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005;172:772-5.
39. Gerhardt S, McDyer J, Girgis R, Conte J, Yang S, Orens J. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168:121-5.
40. Verleden GM, Dupont LJ, Van Raemdonck DE. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J. 2005;25:221-4.
41. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 2005;24:1440-3.
42. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med. 2005;99:208-15.
43. Gotfried M. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest. 2004;125:52S-61S.
44. Alfageme I, Aspa J, Bello S, Blanquer R, Borderías L, et al. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol. 2005;41:272-89.
45. Mandell LA, Wunderink RG, Anzuelo A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America / American Thoracic Society consensus guidelines on the management of community-adquired pneumonia in adults. Clin Infect Dis. 2007;44:527-72.
46. Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev. 2004(4):CD001954.
47. Amsted G. Anti-inflammatory effect of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrobiol Chemother. 2005;55:10-21.
48. Fecik RA, Nguyen PL, Venkatraman L. Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis. Curr Opin Drug Discov Devel. 2005;8:741-7.